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Proteinase-activated receptor 2 belongs to a new G
protein-coupled receptor subfamily activated by
various serine proteases. It has been demonstrated to
play a role during in¯ammation of many tissues
including the skin. Proteinase-activated receptor 2 is
expressed by endothelial cells and regulates cuta-
neous in¯ammation in vivo. The underlying mechan-
isms of proteinase-activated receptor 2 activation in
the skin and the effects on human dermal micro-
vascular endothelial cells, however, are still
unknown. Agonists of proteinase-activated receptor
2 such as mast cell tryptase induce widespread
in¯ammation in many organs including the skin.
Trypsinogen is generated by endothelial cells during
in¯ammation or tumor growth. Therefore we tested
whether human dermal microvascular endothelial
cells express functional proteinase-activated receptor
2 and whether agonists of proteinase-activated recep-
tor 2 regulate in¯ammatory responses in these
cells. Calcium mobilization studies revealed that
proteinase-activated receptor 2 is functional in
human dermal microvascular endothelial cells.
Interleukin-6 and interleukin-8 were upregulated as
detected by reverse transcription polymerase chain
reaction or enzyme-linked immunosorbent assay
indicating a role of proteinase-activated receptor 2 in
stimulating human dermal microvascular endothelial
cells. Electromobility shift assays revealed proteinase-
activated-receptor-2-induced activation of nuclear
transcription factor kB with a maximum after 1 h. In
conclusion, agonists of proteinase-activated receptor
2 upregulate interleukin-6 and interleukin-8 expres-
sion and release in human dermal microvascular
endothelial cells. Thus, proteinase-activated receptor
2 may play an important role in cutaneous in¯am-
mation by mediating in¯ammatory responses on
dermal microvascular endothelial cells and activation
of nuclear transcription factor kB. Key words: in¯am-
mation/G protein-coupled receptor/PAR/proteases/skin. J
Invest Dermatol 118:380±385, 2002
P
roteinase-activated receptor 2 (PAR-2) belongs to a new
subfamily of G protein-coupled receptors with seven
transmembrane domains activated by proteolysis. To
date, four PARs have been cloned and characterized
(Dery et al, 1998; Macfarlane et al, 2001). Tryptase,
trypsin, or neuronal serine proteases are capable of activating
PAR-2 (Steinhoff et al, 2000; Macfarlane et al, 2001). Serine
proteases have clearly been demonstrated to exert important
biologic effects such as tumor growth, development, in¯ammation,
tissue repair, and apoptosis in various tissues including the skin.
Thus, PAR-2 may be important to mediate physiologic and
pathophysiologic effects of serine proteases in the skin.
PAR-2 is expressed by epithelial cells, endothelial cells, smooth
muscle cells, T-cell lines, neutrophils, and neurons (Dery et al,
1998; Coughlin, 2000; Macfarlane et al, 2001). In keratinocytes,
PAR-2 agonists inhibit growth and differentiation (Derian et al,
1996), stimulate secretion of cytokines (Wakita et al, 1997; Hou
et al, 1998), and regulate pigmentation (Seiberg et al, 2000).
Moreover, tryptase activates PAR-2 in human keratinocytes
(Steinhoff et al, 1999). As the in¯ammatory mast cell mediator
tryptase is closely associated with dermal blood vessels, PAR-2 may
mediate in¯ammatory responses of tryptase in cutaneous micro-
vascular endothelial cells.
In macrovascular endothelial cells, the proin¯ammatory medi-
ators tumor necrosis factor a (TNF-a) and interleukin-1a (IL-1a)
upregulate PAR-2 (Nystedt et al, 1996). Moreover, PAR-2
regulates vascular tone in tissues of different origin (Al-Ani et al,
1995) and PAR-2 agonists are mitogenic for endothelial cells
(Mirza et al, 1996).
PAR-2 has been demonstrated to play a signi®cant role in
cutaneous in¯ammation by a neurogenic mechanism (Steinhoff et al,
2000). Additionally, one may speculate that human dermal
microvascular endothelial cells (HDMEC) also express functional
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PAR-2 and that PAR-2 agonists directly affect dermal endothelial
function during in¯ammation and wound healing, e.g., by inducing
cytokine release from dermal endothelial cells.
Although PAR-2 RNA expression was detected in endothelial
cells, the role of PAR-2 for dermal microvascular endothelial cell
regulation is still unknown. Therefore, we investigated the effects
of PAR-2 activation in primary HDMEC. Our aims were (i) to
determine whether PAR-2 is functional in HDMEC by Ca
mobilization studies; (ii) to determine RNA expression and release
of various cytokines involved in endothelial cell (EC) function
using semiquantitative reverse transcription polymerase chain
reaction (RT-PCR) and enzyme-linked polymerase chain reaction
(ELISA); and (iii) to de®ne whether nuclear transcription factor kB
(NFkB) may be involved in transmitting PAR-2-induced changes
in HDMEC function.
MATERIALS AND METHODS
Reagents Trypsin was from Sigma (Deisenhofen, Germany) or
Worthington Biochemical (Freehold, NJ). Human b-tryptase was
expressed in Pichia pastoris (Zettl et al, 2000). Peptides corresponding to
the tethered ligand of human PAR-2 (activating peptide, AP: SLIGKV-
NH2) and the reverse peptide (RP: VKGILS-NH2) or human PAR-4
(PAR-4 AP, AYPGKF-NH2) and reverse peptide (PAR-4 RP,
FKGPYA-NH2) (Dr. McMaster, University of Calgary, Canada) were
used as described previously (Steinhoff et al, 1999, 2000). Fura-2/AM
was from Molecular Probes (Eugene, OR). MMLV reverse transcriptase
and Taq DNA polymerase were from Promega (Mannheim, Germany).
TRIZOL reagent was from Life Technologies (Karlsruhe, Germany).
Nylon ®lters and [a-32P]dCTP were from Amersham (Braunschweig,
Germany). Other reagents were from Sigma.
Measurement of [Ca2+]i HDMEC were incubated in physiologic salt
solution with 2.5 mM Fura-2/AM for 20 min at 37°C (Corvera et al,
1997). Cells were maintained in a microincubator at 37°C and observed
using a Zeiss Fluar 403 objective. Fluorescence was measured in cell
suspensions using a spectro¯uorimeter, as described previously (Steinhoff
et al, 1999). Fluorescence was measured at 340 and 380 nm excitation
and 510 nm emission. The ratio of the ¯uorescence at the two excitation
wavelengths, which is proportional to the [Ca2+]i, was calculated.
Inactivated trypsin or tryptase and PAR-2 RP (VKGILS) or PAR-4 RP
were used as controls (Steinhoff et al, 1999, 2000). Fresh cells were
studied with each agonist and in a minimum of three replicate
experiments.
Cell culture and reagents HDMEC, derived from dermis at the
proliferating stage, were received in 25 cm2 ¯asks (PromoCell,
Heidelberg, Germany). Cells were grown according to the
manufacturer's instructions in endothelial cell basal medium (PromoCell)
supplemented with 5% fetal bovine serum, 0.1 ng per ml epidermal
growth factor, 1.0 mg per ml hydrocortisone, 0.02 mg per ml
gentamicin-25, endothelial cell growth supplement/heparin 2 ml, and
amphotericin-B 2.5 ng per ml. Cells in passage 4 were used for
experiments. In order to verify that cultured HDMEC were free of
contaminating cells, HDMEC were characterized by their typical
cobblestone morphology using light microscopy. Cells for passage 4 were
grown in 100 mm Petri dishes. Trypsin (Life Technologies) was used for
detaching the cells during the splitting at passages 1±3. Accutase (does
not contain trypsin) (PAA Laboratories, Coelbe, Germany) was used for
detaching the cells at the fourth passage.
HDMEC were grown as described above until 80%±90% con¯uence
and cultured overnight in medium containing 2% fetal bovine serum.
Cells were treated either with trypsin (Sigma) at ®nal concentrations 10±7
M or 10±9 M; with AP at ®nal concentrations 5 3 10±5 M or 10±4 M;
10±7 M to 10±9 M tryptase (dissolved in heparin 33.3 mg per ml to
333 mg per ml); or with RP at ®nal concentrations 5 3 10±5 M or 10±4
M. Cells were harvested for RNA preparation and supernatants were
collected at time points 3 h, 6 h, 9 h, 12 h, and 24 h after treatment.
RNA isolation Total RNA was isolated by TRIzol reagent (Life
Technologies) according to the manufacturer's instructions. RNA pellets
were washed with 70% ethanol, dried, and dissolved in 30 ml DNase,
RNase-free water (Promega). To avoid DNA contamination, total RNA
was treated with 10 U RQ1RNase-free DNase I (Promega) for 30 min
at 37°C. The amount of total RNA was measured spectro-
photometrically.
Semiquantitative RT-PCR One microgram RNA was subjected to
reverse transcription using the Promega reverse transcription system in a
®nal reaction volume of 20 ml containing 5 mM MgCl2, 1 3 reverse
transcriptase buffer (Promega), 1 mM each dNTP, 1 U per ml RNAsin,
20 U AMV reverse transcriptase, and 0.5 mg random primers. Tubes
with reaction mixtures were incubated for 10 min at room temperature,
then at 42°C for 30 min with 5 min inactivation of enzyme at 95°C,
and chilled on ice for 5 min. Tubes were kept at ±20°C until use.
For PCR ampli®cations the following primer pairs were used: b-actin,
forward primer 5¢-ATCTGGCACCACACCTTCTACAATGAG-
CTGCG-3¢ and reverse primer 5¢-CGTCATACTCCTGCTTGC-
TGATCCACATCTGC-3¢ (fragment size 838 bp); IL-6, forward primer
5¢- ATGAACTCCTTCTCCACAAGCGC-3¢ and reverse primer 5¢-
GAAGAGCCCTCAGGCTGGACTG-3¢ (628 bp); IL-8, forward primer
5¢-ACGAATTCCTAGGACAAGAGCCAGGAAG-3¢ and reverse pri-
mer 5¢-GTGAATTCAGTGTGGTCCACTCTCAATC-3¢ (253 bp).
For reliable comparison of IL-8 and IL-6 expression with b-actin
mRNA expression (housekeeping gene) in different samples a modi®ed
protocol (Paludan and Thestrup-Pedersen, 1992) was used by making
serial dilutions of template cDNA at constant cycle numbers for each
primer pair to verify that the subsequent PCRs were performed in the
linear range of PCR ampli®cation. For PCR ampli®cation, 20 ml
reactions containing diluted cDNA (1:5 dilution ®rst strain cDNA
received after reverse transcription reaction) were used for IL-6, IL-8;
200 mM dNTP (each); 20±40 pM of each primer, the standard buffer
supplemented with Taq Polymerase (Red Taq kit, Sigma), and 4 U per
reaction of Taq Polymerase. The ampli®cation programs were as follows:
b-actin, one cycle 94°C, 5 min; 58°C, 2 min; 72°C, 1 min; followed by
33 cycles of 94°C, 45 s; 58°C, 45 s; 72°C, 1 min; and a ®nal cycle of
94°C, 45 s; 58°C, 45 s; 72°C, 10 min; IL-6, one cycle 94°C, 5 min;
57°C, 45 s; 72°C, 2 min; followed by 33 cycles of 94°C, 45 s; 57°C,
45 s; 72°C, 2 min; and a ®nal cycle of 94°C, 45 s; 57°C, 45 s; 72°C,
7 min; IL-8, one cycle 94°C, 5 min; 56°C, 35 s; 72°C, 1 min; followed
by 33 cycles of 94°C, 45 s; 56°C, 35 s; 72°C, 1 min; and a ®nal cycle of
94°C, 45 s; 56°C, 35 s; 72°C, 10 min. Aliquots of reaction products
were run on 1.2% agarose gels and product size was analyzed compared
with a coampli®ed control template.
Quanti®cation of PCR products To semiquantify the relative
concentrations of IL-8, IL-6 mRNA, the signal intensity of PCR
products was compared by densitometer reading with that of b-actin
PCR product ampli®ed from the same cDNA in a separate PCR
reaction. The intensity of the ethidium-bromide-stained band of a
speci®c product was densitometrically evaluated using a BioPro®l Video
Densitometer, Image Analysis and Photo Documentation System (CCD
video camera/transilluminator connected to a PC equipped with a frame
grabber video card) with BioPro®l 2-D Image Processing and Analysing
Software (Frobel Labortechnik, Wasserburg, Germany). Densitometric
readings of cytokine products were normalized to the b-actin product
density in the respective sample.
ELISA To study cytokine release by HDMEC, cells were stimulated as
described above for indicated time intervals (3 h, 6 h, 9 h, 12 h, 24 h)
and supernatants were collected and frozen until use for ELISA. For
detection of IL-8, ELISA kits from BioSource (Solingen, Germany) were
used (sensitivity < 2 pg per ml). ELISA was performed with samples
diluted 10 times according to the manufacturer's instructions. To detect
IL-6, ELISA kits from Diaclone (via Biochem, Giessen, Germany) were
used. The ELISA was performed with samples diluted two times
according to the protocol supplied by the manufacturer. The sensitivity
of this kit was < 2 pg per ml. All data were calculated from duplicate
wells and are presented as the mean 6 2SD. The optical density of the
samples was measured with Microplate Reader 3550 Bio-Rad
(Muenchen, Germany) at wavelength 450 nm.
Electromobility shift assay (EMSA) HDMEC (4 3 105) were plated
in six-well plates and allowed to adhere overnight. After treatment with
indicated stimuli cells were washed with phosphate-buffered saline and
lyzed in 60 ml of total-cell-extract buffer [20 mM HEPES, pH 7.9,
350 mM NaCl, 1 mM MgCl2, 0.5 mM ethylenediamine tetraacetic acid,
0.1 mM ethyleneglycol-bis(b-aminoethyl ether)-N,N,N¢,N¢-tetraacetic
acid, 20% (vol/vol) glycerol, 1% (vol/vol) Nonidet P-40, 0.5 mM
dithiothreitol, 2 mM phenylmethylsulfonyl ¯uoride, 50 mg per ml
aprotinin, 10 mg per ml leupeptin] for 15 min on ice. The lysate was
cleared by centrifugation and stored at ±80°C until use for EMSA. Total
cell extracts containing 10 mg of protein were incubated with the 32P-
labeled NFkB-speci®c oligonucleotide (Promega). Binding reactions
were performed in a 20 ml volume containing 4 ml of extract, 4 ml of
5 3 binding buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 1 mM
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dithiothreitol, 2.5 mM MgCl2, and 20% Ficoll), 2 mg poly(dI-dC) as
nonspeci®c competitor DNA, 2 mg of bovine serum albumin, and
50,000 cpm of the labeled oligonucleotide. After a 15 min binding
reaction at room temperature, samples were loaded on a 4%
nondenaturing polyacrylamide gel. After electrophoresis, gels were dried
and exposed to an X-ray ®lm (Amersham). The NFkB-binding
oligonucleotide was end-labeled using [g-32P]ATP and T4
polynucleotide kinase (Life Technologies), followed by P-10 gel ®ltration
(Amersham) to remove nonincorporated radioactivity.
Statistical analysis Results are expressed as average 6 2SD. We
applied analysis of variance to check the signi®cance of average
distinctions. We used a two-population Student's t test, which shows the
reliability even for small sampling (Schmetterer, 1974). The con®dence
level of p < 0.05 was considered signi®cant.
RESULTS
HDMEC express functional PAR-2 To con®rm that
HDMEC express functional PAR-2 we stimulated HDMEC
with speci®c agonists. Tryptase (Fig 1A) and AP (Fig 1B)
stimulated a rapid increase in [Ca2+]i in HDMEC. Trypsin (EC50
»10 nM) or tryptase (EC50 »5 3 10 nM) were 500±1000-fold
more potent (EC50 »10 mM) and 25%±30% more ef®cacious than
AP (not shown). Tryptase (EC50 »10 nM) was 5-fold less potent
than trypsin, but similarly ef®cacious (not shown). There was no
Ca2+ response to 1 nM trypsin preincubated with 10 mg per ml
soybean trypsin inhibitor for 60 min at 37°C before assay. RP had
no effect on [Ca2+]i (Fig 1C). Thus, PAR-2 agonists stimulate
[Ca2+]i speci®cally and effectively in HDMEC. The effect of the
PAR-2 stimulating proteases (trypsin, tryptase) depends upon
enzymatic activity. Moreover, we performed desensitization studies
to investigate a potential role of other PARs that may be stimulated
by trypsin and not by AP. Trypsin failed to completely abolish the
Ca effects by PAR-2 AP (Fig 1D), which is a speci®c PAR-2
agonist (Blackhart et al, 1996). PAR-4 does not appear to be
involved because PAR-4 AP does not exert any effects on
HDMEC (Fig 1B). Moreover, by immunohistochemistry using a
speci®c polyclonal antiserum to PAR-4 (Santa Cruz, CA) and RT-
PCR we were not able to detect PAR-4 in HDMEC cells.
IL-6 and IL-8 mRNA expression in HDMEC is upregulated
upon AP or trypsin stimulation We investigated the
possibility for PAR-2 agonists to stimulate the expression of IL-6
and IL-8 mRNA in HDMEC. This was tested at the following
time points: 3 h, 6 h, 9 h, 12 h, and 24 h after stimulation by
agonists. HDMEC were harvested and total RNA was isolated
from the cells; also the supernatants were collected and frozen until
used for ELISA. Ampli®cation of the b-actin fragment served as
internal control re¯ecting the relative amount of mRNA in each
sample. Results are presented in Fig 2.
IL-6 mRNA AP stimulated increased expression of IL-6 mRNA
at 6 h, 9 h, and 12 h after stimulation compared with unstimulated
controls in HDMEC (Fig 2A). AP at a lower ®nal concentration
(5 3 10±5 M) upregulated the expression of IL-6 more strongly
than higher concentrations at 6 h and 12 h after stimulation. This
may be explained by the effect of desensitization of PAR-2 (Bohm
et al, 1996). Trypsin also upregulates the expression of IL-6 mRNA
by HDMEC at 12 h after stimulation (Table I). Together, these
®ndings indicate that the PAR-2 agonists trypsin and AP upregulate
IL-6 RNA expression in unstimulated HDMEC.
IL-8 mRNA Trypsin stimulated upregulation of IL-8 mRNA
expression between 3 and 12 h (Fig 2B). The maximal effects were
observed at 3 h and 12 h. AP induced upregulation of IL-8 mRNA
between 3 and 12 h with a maximal effect after 12 h. Together,
these ®ndings indicate that the PAR-2 agonists trypsin and AP
upregulate IL-8 RNA expression in unstimulated HDMEC.
Trypsin and AP upregulate the release of IL-6 and IL-8 by
HDMEC After ®nding the effect of the PAR-2 agonists trypsin
and AP on the level of IL-6 and IL-8 mRNA expression we
examined whether these agonists are capable of releasing the
cytokines by HDMEC at similar concentrations. In order to
Figure 1. Ca2+ mobilization studies reveal
dose-dependent activation of PAR-2 by
agonists. (A) Tryptase stimulates PAR-2
activation in a dose-dependent manner with a
maximum at 10±8 M. (B) No increase of
intracellular Ca-mobilization by PAR-4 AP
(5 3 10±5 M), followed by a signi®cant increase
using PAR-2 AP (5 3 10±5 M). (C) Negative
control RP (5 3 10±5 M) fails to stimulate Ca
response in HDMEC. (D) Signi®cant increase of
intracellular Ca-mobilization by AP (5 3 10±5 M),
followed by a weaker increase using trypsin (10±8
M). Experiments were replicated three times.
Thus, HDMEC express functional PAR-2 in vitro.
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investigate the effects of trypsin and AP on IL-6 and IL-8 release we
performed speci®c ELISA with supernatants collected at time
points between 3 h and 24 h.
IL-6 AP upregulates release of IL-6 by HDMEC, with the
maximum effect at 6 h and 12 h after stimulation. Identical to our
®ndings at the RNA level, lower ®nal concentrations of AP (5 3
10±5 M) have stronger effects on IL-6 release at 6 h, but higher
concentrations have stronger effects at 3 h (Fig 3A). RP, as a
negative control, did not show any effect on IL-6 release in
HDMEC. Trypsin also stimulates increased levels of IL-6 by
HDMEC between 3 h and 24 h, with a maximal effect at 12 h.
IL-8 AP signi®cantly increased IL-8 release by HDMEC, with a
maximum at 12 h. Lower concentrations of AP (5 3 10±5 M) had a
more profound effect on IL-8 release than higher concentrations,
but this effect was noticeable only at 6 h (Fig 3B). RP does not
have any effect on the level of IL-8 released by HDMEC (Fig 3B).
Involvement of transcription factor NFkB From recent data,
transcription factor NFkB appears to be a likely candidate for
transactivation of PAR-2-induced responses on cytokine
expression in HDMEC, as IL-6 as well as IL-8 promotors show
the presence of potential NFkB sites (Shimizu et al, 1990; Kunsch
and Rosen, 1993; Stein and Baldwin, 1993).
We examined the involvement of NFkB by testing the capacity
of PAR-2 agonists to activate nuclear translocation of NFkB by
EMSA. Using total cell extracts of HDMEC stimulated with
various concentrations of PAR-2 agonists (trypsin 10±7±10±9 M,
Fig 4A; AP 10±4±10±5 M, Fig 4B) we observed formation of a
complex with the NFkB site. Stimulation by RP did not result in
activation (Fig 4C). This seems to be speci®c as no complex was
observed when the protein extract was incubated under the same
conditions without ligand stimulation (Fig 4). Compared to
positive control (TNF-a) PAR-2 activation resulted in a weaker
but signi®cant upregulation of NFkB (Fig 4). These results
demonstrate that PAR-2 agonists induce NFkB activation in
HDMEC with a maximum after 1 h.
DISCUSSION
Our results demonstrate that PAR-2 is expressed by HDMEC. Ca
mobilization studies reveal that PAR-2 is functional in these cells
and can be activated by tryptase, trypsin, and PAR-2 AP (which is
speci®c for PAR-2; Blackhart et al, 1996), resulting in upregulation
and/or release of the cytokines IL-6 and IL-8. Stimulation of
PAR-2 in HDMEC led to activation of NFkB, an important
intracellular regulator of in¯ammatory responses in endothelial
cells. Thus, PAR-2 may play an important regulatory role of
HDMEC and contribute to in¯ammatory responses in cutaneous
in¯ammation when serine proteases are involved.
First, we have shown that HDMEC express functional PAR-2 as
examined by Ca mobilization studies. Tryptase, trypsin, and AP
stimulated a prompt increase of [Ca2+]i. This agrees with other
studies as functional PAR-2 has been found in several endothelial
cells of different tissues and species (reviewed by Macfarlane et al,
2001). Thus, HDMEC are important target cells of serine proteases
that activate PAR-2.
Mast cells are closely associated with endothelial cells as a
``microvascular unit'' and interact to regulate in¯ammatory
responses, angiogenesis, and wound healing. PAR-2 agonists such
as tryptase from mast cells or trypsin released from endothelial cells
may induce activation of endothelial cells and recruitment of
in¯ammatory cells through the microvascular wall via PAR-2
(Mirza et al, 1997). Endothelial cells are capable of generating
trypsin during in¯ammation and tumorigenesis. In agreement with
this, we have detected trypsinogen RNA in dermal microvascular
endothelial cells by RT-PCR (Bunnett and Steinhoff, unpublished
observation). Consequently, HDMEC may be target cells for
tryptase as well as extrapancreatic trypsin to activate PAR-2 during
cutaneous in¯ammation.
To test this hypothesis, we examined the expression and release
of various cytokines/chemokines from HDMEC at the RNA as
well as the protein level. First, we found that PAR-2 agonists
stimulated upregulation of IL-6 and IL-8 RNA in a time- and
concentration-dependent manner (Fig 2). These results suggest a
selective regulation of cytokine activation in HDMEC.
Upregulation of IL-8 has already been demonstrated in human
keratinocytes indicating an important role of PAR-2 for the
regulation of these cytokines during cutaneous in¯ammation (Hou
et al, 1998). Moreover, we demonstrated increased levels of IL-6
Figure 2. Upregulation of IL-6 and IL-8 mRNA levels in
HDMEC in relation to b-actin expression after treatment of cells
by PAR-2 agonists. Ampli®cation products of IL-6 (628 bp), IL-8
(253 bp), and b-actin cDNA (838 bp) were separated on agarose gels (A,
B) and subjected to densitometric evaluation the results of which are
presented in the graphs. Results are presented as average mean 6 2SD.
*p < 0.05, **p < 0.01, ***p < 0.005 (n = 3 replicates of three
experiments).
Table I. Effects of PAR-2 agonists on IL-6 and IL-8
mRNA expression by HDMEC cells
PAR-2 AP trypsin
RT-PCR 10-4 M 5*10-5 M 10-7 10-9 M
IL-6 3 h ± ± + é
6 h é + ± ±
9 h ++ ++ é ± ±
12 h é ++ + é
24 h ± ± + é
IL-8 3 h ++ ± ++ é
6 h + ++ é ±
9 h ± é é ++
12 h ++ ++ + ++
24 h ± ± ± é
±, Downregulation; ± ±, strong downregulation (>30%); +, upregulation;
++, strong upregulation (>30%); é, absence of signi®cant difference (<5%). If an
experiment was not performed at a particular time point, the corresponding box is
left empty.
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after PAR-2 activation enlarging the regulatory capacity of PAR-2
in human skin. On the other hand, cytokines such as IL-2, IL-4,
IL-12, IL-18, MIF, or chemokines such as MIP-a, MCP-1, or
RANTES, did not respond to PAR-2 activation in HDMEC (data
not shown). These results support the idea of PAR-2 as a receptor
with proin¯ammatory effects in human skin.
This is in agreement with other reports of PAR-2 as a regulator
of endothelial cell function. For example, PAR-2 induces a
subdermal edema (Steinhoff et al, 2000) and NO-dependent
vasorelaxation (Sobey et al, 1999), and can be upregulated by
IL-1, TNF-a, and lipopolysaccharide (Nystedt et al, 1996). PAR-2
agonists induce neutrophil recruitment and leukocyte rolling
(Vergnolle, 1999), suggesting a regulatory role of PAR-2 for
leukocyte±endothelial interaction (Vergnolle et al, 2001). Very
recently, Chi et al (2001) demonstrated IL-6 production via
stimulation of PAR-1 and PAR-2 in macrovascular endothelial
cells. They also observed that both the direct and the endotoxin-
and TNF-a-amplifying effects of PAR agonist peptides on IL-6
production were pertussis toxin sensitive and caused calcium
mobilization. This is in accordance with our results in micro-
vascular endothelial cells indicating an NFkB-dependent activation
of IL-6 and IL-8 release in HDMEC during in¯ammation. These
results are in support of the idea that proteases and other
in¯ammatory stimuli exert amplifying effects during cutaneous
in¯ammation.
From our results, however, it cannot be excluded that PAR-2
may not be the only receptor involved in the biologic responses
induced by trypsin (Schechter et al, 1998; Hollenberg, 1999;
Steinhoff et al, 1999; 2000; Riccardiolo et al, 2000; Shintani et al,
2001), such as PAR-4, for example (Cocks and Moffat, 2000). Our
results strongly indicate that PAR-2 and not PAR-4 is involved in
this process in HDMEC. It cannot be excluded, however, that
other PARs that are not cloned so far (Shintani et al, 2001) may
additionally take part in orchestrating in¯ammatory responses in
HDMEC. Desensitization studies using thrombin, trypsin, PAR-2
AP, and PAR-4 AP show that (i) primary keratinocytes generated
little Ca-response to thrombin (not shown), indicating an insub-
stantial role of PAR-1 that can be activated by trypsin [this is in
agreement with observations by Schechter et al (1998) in human
keratinocytes]; (ii) another receptor (not cloned so far) other than
PAR-2 may be sensitive to trypsin in HDMEC because trypsin fails
to completely abolish the Ca-effects by PAR-2 AP (Fig 1), which
is a speci®c PAR-2 agonist (Blackhart et al, 1996). Also, (iii)
HDMEC do not express PAR-4 as examined by RT-PCR and
Figure 3. Effects of PAR-2 agonists on the levels of IL-6 and IL-8 secreted by HDMEC. The effects of PAR-2 agonist stimulation on
HDMEC IL-6 levels are presented in (A), and on IL-8 levels in (B). HDMEC were cultured in Petri dishes until they reached 80%±90% con¯uence.
Supernatants were collected and subjected to IL-6-speci®c ELISA and IL-8-speci®c ELISA. Statistical analysis was performed by Student's t test. Results
are expressed as average mean of protein concentration (pg per ml) 6 2SD. *p < 0.05, **p < 0.01, ***p < 0.005 (four replicates of two experiments).
Figure 4. PAR-2-induced activation of NFkB in HDMEC. As
shown by EMSA, (A) trypsin (10±7±10±9 M) and (B) AP (5 3 10±5 M)
induced NFkB activation with a maximum after 1 h that was weaker
than for TNF-a but signi®cantly stronger than the negative control. (C)
RP (5 3 10±5 M) failed to induce NFkB activation compared to the
positive control (TNF-a).
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immunohistochemistry (not shown) and are not activated by
PAR-4 AP (Fig 1B); and (iv) using a panel of monoclonal and
polyclonal antibodies to PAR-2 (PAR2-2C, Dr. Derian, Johnson
& Johnson, Spring Field; PAR2-B5, Dr. Hollenberg, University of
Calgary, Canada; PAR2-SAM11 and PAR2-N19, Santa Cruz,
CA) we observed increased immunoreactivity in microvascular
endothelial cells of human skin samples with in¯ammatory skin
diseases, supporting the idea of a role of PAR-2 in HDMEC during
in¯ammation in vivo.1 In summary, these results strongly indicate
that besides PAR-2 other PARs, except PAR-4, which are not
cloned so far and which can be stimulated by trypsin, may be
additionally involved in regulating HDMEC.
NFkB is well known as an important intracellular regulator of
in¯ammation and growth in endothelial cells (Takeuchi and
Baichwal, 1995). As NFkB stimulates cytokine release from
HDMEC we tested whether PAR-2 agonists may induce NFkB
activation. Indeed, all agonists of PAR-2 (trypsin, tryptase, and AP)
stimulated NFkB activation with a maximum after 1 h indicating a
regulatory role of the NFkB pathway through PAR-2. The precise
PAR-2-mediated NFkB-signaling pathway is currently under
investigation.
From these data we hypothesize that agonists of PAR-2 may
induce the upregulation/release of proin¯ammatory cytokines
(IL-6, IL-8) from HDMEC and activate important in¯ammatory
signaling cascades (NFkB-pathway). Thus, PAR-2 may be an
important link for the cell±cell communication between mast cells
and HDMEC during in¯ammation. In conclusion, besides the role
of PAR-2 during neurogenic in¯ammation (Steinhoff et al, 2000)
this receptor may also exert a direct regulatory role on human
microvascular endothelial cells during cutaneous in¯ammation.
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